1Mattson MP. Pathways towards and away from Alzheimer′s disease [ J ]. Nature ,2004 ;430 (7000) :631-639.
2Alas KD. Cerebrospinal fluid levels of Aβ1-42 and tau:potential markers of Alzheimer disease[ J]. Neurol Transmission, 1998,53:321-329.
3Haas J, Storch-Hagenlocher B, Biessmann A ,et al. Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro [ J ]. Neurosci Lett, 2002,322 ( 2 ) : 121-125.
4Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimerg disease mouse model[ J ]. Science ,2007,316 ( 5825 ):750-754.
5Sun X, He G, Qing H, et al. Hypoxia facilitates Alzheimer's disease pathoger/esis by up-regulating BACE1 gene expression [ J]. Proc Natl Acad Sci U S A,2006,103(49):18727-18732.
6Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance[ J]. Biol Chem ,2003,278 (22) : 19575-19578.
7Sun X,Tong Y, Qing H, Chen CH, et al. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome[ J]. FASEB ,2006,20 (9) : 1361-1368.
8Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor lalpha (HIF-lalpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation[ J ]. Biol Chem ,2007,282( 15 ) : 10873-10880.
9Candore G, Balistrerl CR, Grimaldi MP, et al. Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer′s disease [ J ]. Ann N Y Acad Sci,2006,1089:472-486.
10Hwndersen V, Buckwaocter JG. Cognitive deficits of men and women with Aizhermei [ J ]. Neurology, 1994,44 : 90 -96.
二级参考文献70
1杨蜀莲.血管性痴呆[J].中风与神经疾病杂志,1987,4(1):1-4.
2Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon 4 allele, elevated midlffe total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzhekner disease. Ann Intern Med, 2002. 137:149 - 155.
3Meyer JS, Rauch G, Rauch RA, et al. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Nenrobiol Aging, 2000, 21 : 161 - 169.
4Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet, 1996, 347:1141 - 1145.
5Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brah weight at death: the HAAS. Honokdu-Asia aging Study. Neurobiol Aging, 2000, 21:57 -62.
6de la Torre JC. Cerebral hypoperfusion, capiliary degeneration, and development of Alzhehner disease. Alzheimer Dis Assoc Disord, 2000,14(Suppl 1): S72 -S81.
7Swan GE, DeCarli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology, 1998, 51:986 -993.
8DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose m 51 healthy adults. Neurology, 1995,45: 2077 - 2084.
9Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261:921 -923.
10Zarow C, Zaias B, Lyness SA, et al. Cerebral amyioid angiopathy Alzhehner disease is associated with apolipoprotein E4 and cortical neuron loss. Alzheimer Dis Assoc Disord, 1999, 13:1 -8.
9Roger N, Rosenberg MD. Translational research on the way to effective therapy for Alzheimer disease [ J]. Arch Gen Psychiatry,2005, 62( 11 ) :1186-1192.
10Lewczuk P,Esselmann H,Bibl M,et al. Tan protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease:original data and review of the literature [ J ]. Mol Neurosci, 2004, 23 ( 2 ) : 115 -222.
